Health Canada Approves ALK's RAGWITEK® Sublingual Allergy Immunotherapy (SLIT)-Tablets for Pediatric Patients with Ragweed Allergy
Share this article Share this article - With the indication expanded to pediatric patients, ALK Canada now provides adults and children a SLIT-tablet option to treat allergies to ragweed pollen, one of the most common allergens found in the provinces of Ontario and Quebec - MISSISSAUGA, ON, Dec. 22, 2020 /CNW/ -- Today ALK, a global, research-driven pharmaceutical company, announced that Health Canada has approved once-daily RAGWITEK® (Standardized Allergen Extract, Short Ragweed (Ambrosia artemisiifolia) Sublingual Tablet) for the treatment of moderate to severe ragweed pollen allergies in ...
Source: newswire.ca